Dimberg J, Shamoun L, Landerholm K, Wågsäter D. Effects of diabetes type 2 and metformin treatment in Swedish patients with colorectal cancer. World J Gastroenterol 2022; 28(19): 2148-2151 [PMID: 35664033 DOI: 10.3748/wjg.v28.i19.2148]
Corresponding Author of This Article
Dick Wågsäter, PhD, Professor, Department of Medical Cell Biology, Uppsala University, D1:3, Husargatan 3, Uppsala 751 23, Sweden. dick.wagsater@mcb.uu.se
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 21, 2022; 28(19): 2148-2151 Published online May 21, 2022. doi: 10.3748/wjg.v28.i19.2148
Effects of diabetes type 2 and metformin treatment in Swedish patients with colorectal cancer
Jan Dimberg, Levar Shamoun, Kalle Landerholm, Dick Wågsäter
Jan Dimberg, Department of Natural Science and Biomedicine, School of Health and Welfare, Jönköping University, Jönköping 551 11, Sweden
Levar Shamoun, Department of Laboratory Medicine and Pathology, Region Jönköping County, Jönköping 553 05, Sweden
Levar Shamoun, Dick Wågsäter, Department of Medical Cell Biology, Uppsala University, Uppsala 751 23, Sweden
Kalle Landerholm, Department of Surgery, Region Jönköping County, Jönköping 553 05, Sweden
Kalle Landerholm, Department of Biomedical and Clinical Sciences, Linköping University, Linköping 581 85, Sweden
Author contributions: Dimberg J and Wågsäter D designed and coordinated the study; Shamoun L performed the experiments, and acquired and analysed the data; Dimberg J, Shamoun L, Landerholm K, and Wågsäter D interpreted the data; Landerholm K recruited the patients; Dimberg J, Landerholm K, and Wågsäter D wrote the manuscript; all authors made critical revisions to the manuscript and approved the final version of the article.
Supported bythe Medical Research Council of Southeast Sweden, No. FORSS-931897; and the Division of Medical Diagnostics of Region Jönköping County, No. Futurum-970572.
Conflict-of-interest statement: The study was supported by grants from Medical Research Council of Southeast Sweden (FORSS-931897) and Division of Medical Diagnostics (Futurum-970572), Region Jönköping County, Sweden. The funding organizations had no role in the design, management, analysis, interpretation of the data, preparation, review, or approval of the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dick Wågsäter, PhD, Professor, Department of Medical Cell Biology, Uppsala University, D1:3, Husargatan 3, Uppsala 751 23, Sweden. dick.wagsater@mcb.uu.se
Received: December 16, 2021 Peer-review started: December 16, 2021 First decision: January 27, 2022 Revised: February 1, 2022 Accepted: April 9, 2022 Article in press: April 9, 2022 Published online: May 21, 2022 Processing time: 151 Days and 22.2 Hours
Abstract
The association between type 2 diabetes mellitus (DM) and colorectal cancer (CRC) has been thoroughly investigated and reports have demonstrated that the risk of CRC is increased in DM patients. The association between DM and the survival of patients with CRC is controversial. Evidence suggests that metformin with its anti-inflammatory effects is a protective factor against the development of CRC among DM patients and that metformin therapy is associated with a better prognosis in patients with DM. In our cohort, we did not find any associations between the presence of DM or metformin and cancer specific survival or any relation to plasma levels of a panel of 40 inflammatory factors and irisin. On the other hand, we identified that the insulin-like growth factor binding protein 7 single nucleotide polymorphism rs2041437 was associated with DM in CRC patients. The dominance of the T bearing genotypes in patients with DM was statistically significant (P = 0.038), with an odds ratio of 1.66 (95% confidence interval: 1.03-2.69).
Core Tip: Type 2 diabetes mellitus (DM) or metformin treatment does not influence mortality in colorectal cancer (CRC). Type 2 DM or metformin does not influence the levels of inflammatory factors in plasma in patients with CRC. Single nucleotide polymorphisms of insulin-like growth factor binding protein 7 are associated with type 2 DM in patients with CRC.
